Here are the 10-Q quarterly reports from Faeth Therapeutics, Inc. (FTH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTH filings page.
Faeth Therapeutics, Inc. reported a $206.6 million net loss for the nine months ended September 30, 2026, versus $16.4 million a year earlier. The loss included $133.0 million of acquired in-process research and development expense from the February acquisition of Legacy Faeth; research and development expense was $38.9 million versus $8.8 million. The acquisition coincided with a private placement generating $200.0 million in gross proceeds. Cash, cash equivalents and marketable securities were $174.8 million at September 30, 2026; the company expects that balance to fund operations for at least 12 months from issuance.
PIKTOR, an oral combination for endometrial and breast cancer, is in a Phase 2 trial for advanced endometrial cancer, with topline data anticipated by year-end 2026; its Phase 1b/2 trial for HR+/HER2- advanced breast cancer began dosing in April 2026, with interim data expected in 2027. In August 2026, the FDA granted Fast Track designation to PIKTOR with paclitaxel for advanced or recurrent endometrial cancer with a PI3K/AKT/mTOR pathway alteration after platinum-based chemotherapy and an immune checkpoint inhibitor. Faeth expects operating losses and negative operating cash flows for the foreseeable future.
Faeth Therapeutics, Inc. reported a net loss of $186.2 million for the six months ended June 30, 2026, largely driven by a $133.0 million acquired in-process R&D charge recognized in connection with its February 2026 acquisition of Faeth Therapeutics and related programs.
Excluding that nonrecurring charge, operating costs expanded as research and development expenses rose to $27.1 million and general and administrative expenses to $28.9 million, reflecting integration of the acquired business, higher personnel costs, and stock-based compensation. Cash, cash equivalents and marketable securities totaled $186.4 million as of June 30, 2026, following a $200.0 million Series B preferred stock private placement and subsequent conversion of most preferred shares into common stock.
Post-transaction, legacy Sensei stockholders held about 4.9% of the common equity on a fully diluted basis, former Faeth holders 40.6%, and new private placement investors 54.5%. Management states that the strengthened balance sheet is expected to fund operations through key clinical milestones for lead multi-node PI3K/AKT/mTOR inhibitor PIKTOR in endometrial and HR+/HER2- breast cancer.